获得人才项目：
2021，上海市人才发展资金资助
获得奖项：
2019，复旦大学优秀博士后;
2020，“一健康基金”新冠肺炎疫情防控特别奖，优秀教师三等奖；
2021，第六届中国科协优秀科技论文奖。
研究方向：
1. 人冠状病毒感染机制的研究
2. 广谱抗人冠状病毒入侵抑制剂的研究
科研项目：
1. 国家自然科学基金委员会, 青年项目, 82002142, 高效广谱抗冠状病毒新型拟肽类抑制剂的功能及抗病毒机制的研究, 2020-01至2021-12, 16万元, 在研, 主持；
2. 国家科技部，重大专项项目，SQ2018ZX100301,
防治重大呼吸道病毒感染疾病的原创生物技术产品研发及战略储备, 2018-01至2020-12, 4080万元, 结题, 课题骨干；
3. 复旦大学引进人才项目、中国博士后基金等
代表性论著（不超过5篇/部）：
1. Xia, Shuai#; Chan, Jasper Fuk-Woo#; Wang, Lijue#; Jiao, Fanke; Kenn Ka-Heng Chik; Chu,
Hin; Lan, Qiaoshuai; Xu, Wei; Wang, Qian; Wang, Chao; Yuen, Kwok-Yung; Lu, Lu; Jiang,
Shibo; Peptide-based pan-CoV fusion inhibitors maintain high potency against
SARS-CoV-2 Omicron variant. Cell Research. 2022. 1-3.
2. Xia, Shuai#;
Liu, Meiqin#; Wang, Chao#; Xu, Wei#; Lan, Qiaoshuai; Feng, Siliang; Qi, Feifei;
Bao, Linlin; Du, Lanying; Liu, Shuwen; Qin, Chuan; Sun, Fei; Shi, Zhengli; Zhu,
Yun*; Jiang, Shibo*; Lu, Lu*; Inhibition of SARS-CoV-2 (previously 2019-nCoV)
infection by a highly potent pan-coronavirus fusion inhibitor targeting its
spike protein that harbors a high capacity to mediate membrane fusion. Cell
Research, 2020, 30(4): 343-355.
3. Xia Shuai#,
Lan Qiaoshuai#, Zhu Yun#, Wang Chao#, Xu Wei#, Li Yutang, Wang Lijue, Jiao
Fanke, Zhou Jie, Hua Chen, Wang Qian, Cai Xia, Wu Yang, Gao Jie, Liu Huan, Sun
Ge, Jan Münch, Frank Kirchhoff, Yuan Zhenghong*, Xie Youhua*, Sun Fei*, Jiang
Shibo*, Lu Lu* Structural and functional basis for pan-CoV fusion inhibitors
against SARS-CoV-2 and its variants with preclinical evaluation. Signal
Transduction and Targeted Therapy (2021), 6(1):288.
4. Xia, Shuai#;
Lan, Qiaoshuai#; Su, Shan#; Wang, Xinling#; Xu, Wei; Liu, Zezhong; Zhu, Yun;
Wang, Qian*; Lu, Lu*; Jiang, Shibo* The role of furin cleavage site in
SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of
trypsin. Signal Transduction and Targeted Therapy (2020) 5:92
5. Xia, Shuai#;
Yan, Lei#; Xu, Wei#; Agrawal, Anurodh Shankar; Algaissi, Abdullah; Tseng, Chien
Te K; Wang, Qian; Du, Lanying; Tan, Wenjie; Wilson, IanA*; Jiang, Shibo*; Yang,
Bei*; Lu, Lu*; A pan-coronavirus fusion inhibitor targeting the HR1 domain of
human coronavirus spike, Science Advances, 2019, 5(4):
0-eaav4580.
代表性专利（不超过5项）：
1. 广谱地抑制人类冠状病毒感染的多肽及其应用 (已授权：CN201610070216.4）
2. 多肽、其制备方法和用途（申请号：CN202180001804.1）